Scientists reprogram immune cells to hunt deadly sarcomas
NCT ID NCT04995003
Summary
This early-stage study is testing the safety of a two-part treatment for advanced sarcomas that have stopped responding to standard therapies. Doctors take a patient's own immune cells, genetically modify them to recognize and attack cancer cells, and then infuse them back. These modified cells are given alongside an immunotherapy drug designed to help the immune system fight cancer longer. The study will enroll up to 25 young patients (ages 1-25) to see if this combination is safe and if it shows signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.